Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation

Trial Profile

Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms LIBER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2021.
    • 20 Jul 2012 Planned number of patients changed from 724 to 386 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top